---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-022240"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-14T00:23:06.477667+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zentalis prices public offering of 11M shares at $22.66, raising ~$235.5M

## Summary
- Sale of 11,032,656 common shares at $22.66 per share; net proceeds estimated at $235.5M.
- Net proceeds to be used for ongoing and planned clinical trials and working capital.
- Closing expected on June 20, 2023, subject to customary conditions.
- Underwriters include Morgan Stanley, Jefferies, and SVB Securities.
- Offering conducted under effective shelf registration statement on Form S-3.

## SEC filing metadata
- accession: 0001628280-23-022240
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000162828023022240/0001628280-23-022240-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000162828023022240/zntl-20230615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-022240
- JSON: https://secwatch.observer/filing/0001628280-23-022240.json
- Plain text: https://secwatch.observer/filing/0001628280-23-022240.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.